Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando. BEAM-101 is an investigational genetically modified ex vivo cell therapy for the treatment of SCD with severe vaso-occlusive crises (VOCs). “Approximately eight million people worldwide live with sickle cell disease, a condition that can severely affect the function of multiple organs, diminish quality of life, and result in a shortened life span. These patients have a significant unmet need for additional safe and effective treatment options. BEAM-101, designed to be a one-time, disease-modifying therapy, has the potential to m
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]Forbes
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- BEAM's page on the SEC website